A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry

• Published in: Annals of the rheumatic diseases Vol. 76; no. 8; pp. 1426 - 1431
• Main Authors: Glintborg, Bente, Sørensen, Inge Juul, Loft, Anne Gitte, Lindegaard, Hanne, Linauskas, Asta, Hendricks, Oliver, Hansen, Inger Marie Jensen, Jensen, Dorte Vendelbo, Manilo, Natalia, Espesen, Jakob, Klarlund, Mette, Grydehøj, Jolanta, Dieperink, Sabine Sparre, Kristensen, Salome, Olsen, Jimmi Sloth, Nordin, Henrik, Chrysidis, Stavros, Dalsgaard Pedersen, Dorte, Sørensen, Michael Veedfald, Andersen, Lis Smedegaard, Grøn, Kathrine Lederballe, Krogh, Niels Steen, Pedersen, Lars, Hetland, Merete Lund
• Format: Journal Article
• Language: English
• Published: England BMJ Publishing Group LTD 01.08.2017
• Subjects: Adult; Aged; Ankylosing spondylitis; Antibodies, Monoclonal - therapeutic use; Antirheumatic Agents - therapeutic use; Arthritis, Psoriatic - drug therapy; Arthritis, Rheumatoid - drug therapy; Biosimilar Pharmaceuticals; Clinical outcomes; Comorbidity; Denmark; Drug Substitution; Female; Humans; Immunotherapy; Inflammation; Inflammatory bowel disease; Inflammatory diseases; Infliximab; Male; Middle Aged; Monoclonal antibodies; Patients; Psoriatic arthritis; Registries; Rheumatic diseases; Rheumatoid arthritis; Spondylarthropathies - drug therapy; Spondylitis; Studies; TNF inhibitors; Treatment Outcome; Tumor necrosis factor-α; Denmark; Ankylosing Spondylitis; Anti-TNF; Outcomes research; Rheumatoid arthritis; Psoriatic arthritis

ObjectivesAccording to guidelines, a nationwide non-medical switch from originator (INX, Remicade) to biosimilar infliximab (Remsima, CT-P13) was conducted in Danish patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (AxSpA). We investigated disease activi...